Recently, Warner Pharmaceuticals (688799. SH) received the "Drug Registration Certificate" of carboprost tromethamine injection approved and issued by the State Drug Administration, which is the company's first obstetric drug and another important product of the company's layout in addition to the three advantageous areas of digestion, respiration and anti-infection.

According to the announcement, carboprost tromethamine injection is mainly suitable for abortion at 13 weeks to 20 weeks of pregnancy and postpartum hemorrhage caused by uterine contraction relaxation that is ineffective in conventional treatment. The company's carboprost tromethamine injection has obtained the drug registration certificate according to the newly registered classification of chemical drugs in category 4, and is deemed to have passed the consistency evaluation.

At present, carboprost tromethamine injection has been included in many authoritative guidelines at home and abroad. According to the database of Moentropy Pharmaceutical, a third-party research institution, the terminal sales of carboprost tromethamine injection in hospitals in 2021, 2022, and 2023 will be 728 million yuan, 729 million yuan, and 602 million yuan respectively.

Huana Pharmaceutical said that the drug registration certificate of carboprost tromethamine injection has further enriched the company's preparation product varieties and has positive significance for optimizing the company's product structure.

In recent years, Huana Pharmaceutical has continued to increase R&D investment, further consolidating the company's competitive advantages in the fields of digestion, respiration and anti-infection, while also expanding new therapeutic areas. In January 2025, the company's first ophthalmic diquafosol sodium eye drops were approved; The approval of carboprost tromethamine injection marks the company's first product layout in the field of obstetrics.

It is understood that after more than 20 years of development, Huana Pharmaceutical Factory has the production capacity of tablets, capsules, granules, powders, dry suspensions, inhalation solutions, small-volume injections, eye drops, lyophilized powder injections and other dosage form preparation products.